| Publications | PubMed=4912237; DOI=10.1128/JVI.1.5.1045-1051.1967; PMCID=PMC375384
Hinuma Y., Konn M., Yamaguchi J., Wudarski D.J., Blakeslee J.R. Jr., Grace J.T. Jr.
Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.
J. Virol. 1:1045-1051(1967) PubMed=4321017; DOI=10.1002/ijc.2910060315
Durr F.E., Monroe J.H., Schmitter R., Traul K.A., Hirshaut Y.
Studies on the infectivity and cytopathology of Epstein-Barr virus in human lymphoblastoid cells.
Int. J. Cancer 6:436-449(1970) PubMed=4321974
Maurer B.A., Imamura T., Wilbert S.M.
Incidence of EB virus-containing cells in primary and secondary clones of several Burkitt lymphoma cell lines.
Cancer Res. 30:2870-2875(1970) PubMed=4932228; DOI=10.1002/ijc.2910070214
Gergely L., Klein G., Ernberg I.
The action of DNA antagonists on Epstein-Barr virus (EBV)-associated early antigen (EA) in Burkitt lymphoma lines.
Int. J. Cancer 7:293-302(1971) PubMed=4115493
Petit P., Verhest A., Lecluse-van der Bilt F.A., Jongsma A.P.M.
The chromosomes of the EB virus-positive Burkitt cell line P3J.HR1K studied by the fluorescent staining technique.
Pathol. Eur. 7:17-21(1972) PubMed=4122458; DOI=10.1002/ijc.2910100108
Klein G., Dombos L., Gothoskar B.
Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.
Int. J. Cancer 10:44-57(1972) PubMed=4364259; DOI=10.1002/ijc.2910110210
Klein G., Dombos L.
Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome.
Int. J. Cancer 11:327-337(1973) PubMed=168255; DOI=10.4049/jimmunol.115.1.243
Hutt L.M., Huang Y.-T., Dascomb H.E., Pagano J.S.
Enhanced destruction of lymphoid cell lines by peripheral blood leukocytes taken from patients with acute infectious mononucleosis.
J. Immunol. 115:243-248(1975) PubMed=170370; DOI=10.1099/0022-1317-28-2-207
Adams A., Strander H., Cantell K.
Sensitivity of the Epstein-Barr virus transformed human lymphoid cell lines to interferon.
J. Gen. Virol. 28:207-217(1975) PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977) PubMed=913957; DOI=10.20772/cancersci1959.68.3_357
Inada T., Kasuga T., Nojiri I., Hiraoka T., Furuse T.
Comparative study on radiosensitivities of cultured cell lines derived from several human tumors under hypoxic condition.
Gann 68:357-362(1977) PubMed=6265077
Pizzo P.A., Chattopadhyay S.K., Magrath I.T., Del Giacco E., Sherrick D., Gray T.E.
Examination of Epstein-Barr virus and C-type proviral sequences in American and African lymphomas and derivative cell lines.
Cancer Res. 41:3165-3171(1981) PubMed=6278187; DOI=10.1093/jnci/68.2.179
Zeuthen J., Klein G., Ber R., Masucci G., Bisballe S., Povey S., Terasaki P.I., Ralph P.
Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. I Isolation, characterization, cell surface markers, and B-cell markers.
J. Natl. Cancer Inst. 68:179-195(1982) PubMed=6278188; DOI=10.1093/jnci/68.2.197
Klein G., Zeuthen J., Ber R., Ernberg I.
Human lymphoma-lymphoma hybrids and lymphoma-leukemia hybrids. II Epstein-Barr virus induction patterns.
J. Natl. Cancer Inst. 68:197-202(1982) PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336
Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd-Kulikowsk H.D., Parsons R.G.
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
J. Immunol. 129:1336-1342(1982) PubMed=6287082; DOI=10.1093/jnci/69.3.585
Gerber P., Ablashi D.V., Magrath I.T., Armstrong G.R., Andersen P., Trach L.
Persistence of transforming and nontransforming Epstein-Barr virus in high passages of P3HR-1 cell lines.
J. Natl. Cancer Inst. 69:585-590(1982) PubMed=6231253; DOI=10.1002/ijc.2910330407
Ehlin-Henriksson B., Klein G.
Distinction between Burkitt lymphoma subgroups by monoclonal antibodies: relationships between antigen expression and type of chromosomal translocation.
Int. J. Cancer 33:459-463(1984) PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986) PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990) PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x; PMCID=PMC452998
Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.
p53 is frequently mutated in Burkitt's lymphoma cell lines.
EMBO J. 10:2879-2887(1991) PubMed=2052620; DOI=10.1073/pnas.88.12.5413; PMCID=PMC51883
Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991) PubMed=8220424; DOI=10.1038/ng0993-56
Bhatia K.G., Huppi K., Spangler G., Siwarski D., Iyer R., Magrath I.T.
Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.
Nat. Genet. 5:56-61(1993) PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493
Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T.
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.
FASEB J. 7:951-956(1993) PubMed=8402660
O'Connor P.M., Jackman J., Jondle D., Bhatia K.G., Magrath I.T., Kohn K.W.
Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines.
Cancer Res. 53:4776-4780(1993) PubMed=8108117
Albert T., Urlbauer B., Kohlhuber F., Hammersen B., Eick D.
Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines.
Oncogene 9:759-763(1994) PubMed=12068308; DOI=10.1038/nature00766
Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002) PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x; PMCID=PMC11160262
Maesako Y., Uchiyama T., Ohno H.
Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma.
Cancer Sci. 94:774-781(2003) PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009) PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010) PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012) PubMed=25355872; DOI=10.1128/JVI.02570-14; PMCID=PMC4301145
Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
J. Virol. 89:713-729(2015) PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015) PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017) PubMed=30285677; DOI=10.1186/s12885-018-4840-5; PMCID=PMC6167786
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940.1-940.13(2018) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019) |
|---|
